10 Results for "

B cell subsets

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "B cell subsets" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99459
CAS No.: 909110-25-4
Synonyms: BG 9924; TT-47

Target:  

TNF Receptor CXCR

Research Areas:  

Inflammation/Immunology

Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .
loading...
    loading...
Cat. No.: HY-P990690
CAS No.: 2407760-40-9
Synonyms: MEDI-5752

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Cancer

Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
loading...
    loading...
Cat. No.: HY-150749A
Purity:  99.82%
Target:  

IFNAR

Research Areas:  

Cancer

ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
loading...
    loading...
Cat. No.: HY-117622
CAS No.: 1388894-17-4
Target:  

IRAK

Research Areas:  

Inflammation/Immunology Cancer

ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
loading...
    loading...
Cat. No.: HY-164002
CAS No.: 1609465-78-2
Target:  

Btk

Research Areas:  

Others

PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC50=0.64 nM). The melamine portion of PF-303 forms a covalent bond with BTK's Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent BTK inhibitors. PF-303 can be used to model and study the effects of BTK inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation .
loading...
    loading...
Cat. No.: HY-150749
CAS No.: 1198621-85-0
Target:  

IFNAR

Research Areas:  

Inflammation/Immunology Cancer

ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
loading...
    loading...
Cat. No.: HY-P992348

Research Areas:  

Inflammation/Immunology

DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-P11705
Research Areas:  

Cancer

PUMA2A is a PUMA BH3-only peptide. PUMA2A can be used as a negative control in Cytochrome C release assays and BH3 profiling. PUMA2A can be used in the research of chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-D3197
CDg16 is a selective fluorescent dye targeting SLC18B1 (λabsem=458/544 nm) that is actively transported into lysosomal vesicles of activated macrophages independent of the endocytic pathway. CDg16 enables highly specific vesicle localization in live cells. CDg16 exhibits no cytotoxicity and accurately distinguishes activated M1 and M2 subsets from different origins. CDg16 shows low background staining in non-activated cells and normal organs, making it suitable for time-lapse imaging. In preclinical animal models of inflammatory sites, atherosclerotic plaques and liver inflammation, CDg16 allows visualization of activated macrophages. CDg16 can be used to study inflammation-related diseases and atherosclerosis .
loading...
    loading...
Cat. No.: HY-19009B
CAS No.: 126595-07-1
Target:  

CCR

Propagermanium is an orally active and selective CCR2 inhibitor. Propagermanium enhances IFN-γ, IL-2, 2',5'-oligoadenylate synthetase, and unspecified cytokine production, and induces mature cytolytic NK cell subsets. Propagermanium reduces HBe antigen and HBV DNA polymerase levels, promotes HBV clearance and lowers serum ALT. Propagermanium downregulates STAT1, inhibits pro-inflammatory microglia polarization, pro-inflammatory cytokine release, and monocyte/macrophage infiltration. Propagermanium can be used for the research of chronic hepatitis B, atherosclerosis, breast cancer, non-alcoholic steatohepatitis, insulin resistance, refractory gastric cancer, multiple myeloma, type 2 diabetes .
loading...
    loading...